Atlas Trials

RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

Clinical trial NCT02003092 · TERMINATED

Trial details

NCT number
NCT02003092
Sponsor
Rexahn Pharmaceuticals, Inc.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Solid TumorTriple Negative Breast Cancer
Start date
2013-08-01
Primary completion
2019-10-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.